Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MIRM Mirum Pharmaceuticals, Inc.

未开盘 07-22 16:00:00 EDT

114.48

-2.57

-2.20%

盘后114.48

+0.000.00%

19:34 EDT

最高117.17	最低114.34	成交量44.20万
今开116.87	昨收117.05	日振幅2.41%
总市值69.81亿	流通市值60.06亿	总股本6,098万
成交额5,081万	换手率0.84%	流通股本5,246万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MIRM","market":"US","secType":"STK","nameCN":"Mirum Pharmaceuticals, Inc.","latestPrice":114.48,"timestamp":1784750400000,"preClose":117.05,"halted":0,"volume":441965,"hourTrading":{"tag":"盘后","latestPrice":114.48,"preClose":114.48,"latestTime":"19:34 EDT","volume":9042,"amount":1035123.53,"timestamp":1784763247113,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.021956428876548424,"floatShares":52459138,"shares":60977800,"eps":-13.6,"marketStatus":"未开盘","change":-2.57,"latestTime":"07-22 16:00:00 EDT","open":116.87,"high":117.165,"low":114.34,"amount":50805326.3952,"amplitude":0.024135,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.6,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784793600000},"marketStatusCode":0,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":117.05,"preHourTrading":{"tag":"盘前","latestPrice":117.05,"preClose":117.05,"latestTime":"08:44 EDT","volume":16,"amount":1872.79008,"timestamp":1784724248395,"change":0,"changeRate":0,"amplitude":0.000085},"postHourTrading":{"tag":"盘后","latestPrice":114.48,"preClose":114.48,"latestTime":"19:34 EDT","volume":9042,"amount":1035123.53,"timestamp":1784763247113,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.021949,"impliedVol":0.4496,"impliedVolPercentile":0.58},"requestUrl":"/m/hq/s/MIRM","defaultTab":"news","newsList":[{"id":"1174266617","title":"Mirum制药与因塞特医疗公布Zilurgisertib治疗进行性骨化性纤维发育不良的关键2期研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174266617","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174266617?lang=zh_cn&edition=full","pubTime":"2026-06-15 04:36","pubTimestamp":1781469383,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 与因塞特医疗联合宣布，其候选药物Zilurgisertib在治疗进行性骨化性纤维发育不良的关键性2期PROGRESS研究中，取得了积极的顶线结果。与安慰剂相比，接受Zilurgisertib治疗的患者在关键疾病活动指标上表现出显著改善。安全性方面，Zilurgisertib的耐受性普遍良好，观察到的不良事件与先前研究数据一致。此次积极数据标志着在治疗这种罕见、致残性遗传疾病方面的一个重要进展。两家公司正与监管机构讨论下一步开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","INCY","BK4139","BK4585","BK4550","MIRM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105034196","title":"Mirum Pharmaceuticals在欧洲肝病研究学会国际肝病大会上公布罕见肝病项目新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1105034196","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105034196?lang=zh_cn&edition=full","pubTime":"2026-05-31 00:00","pubTimestamp":1780156813,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. (MIRM) 宣布，其针对罕见肝病的研究项目所取得的最新数据，已在2026年欧洲肝病研究学会（EASL）国际肝病大会上正式公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104283418","title":"异动解读 | 药物研究进展获分析师看好，Mirum Pharmaceuticals盘中大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104283418","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104283418?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:54","pubTimestamp":1778680466,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.今日盘中股价大涨5.26%，引起了市场的广泛关注。消息面上，该公司近期宣布其用于治疗罕见肝病的药物volixibat在一项中期研究中达到了主要目标，这一积极的临床进展增强了市场对公司研发管线的信心。与此同时，公司也完成了总额6亿美元的可转换优先票据的定价工作，并计划将部分募集资金用于赎回2029年到期的部分票据，以优化其债务结构。这一系列的公司动态共同构成了推动股价上涨的重要因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177923329","title":"Mirum Pharmaceuticals完成6亿美元可转换优先票据定价 并部分赎回2029年到期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1177923329","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177923329?lang=zh_cn&edition=full","pubTime":"2026-05-13 11:56","pubTimestamp":1778644574,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布完成总额6亿美元的可转换优先票据发行的定价工作。与此同时，公司计划将此次发行所得款项的一部分，用于赎回其2029年到期的部分可转换票据，以实现债务结构的优化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193143463","title":"Mirum制药Volixibat安全性特征与IBAT抑制作用一致 主要表现为胃肠道事件及肝酶升高","url":"https://stock-news.laohu8.com/highlight/detail?id=1193143463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193143463?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:10","pubTimestamp":1777896611,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals公司公布的研究数据显示，其核心候选药物volixibat的安全性特征与回肠胆汁酸转运蛋白（IBAT）抑制机制高度吻合。临床观察发现，该药物引发的不良反应主要集中于胃肠道范畴，同时伴有肝脏生化参数的可逆性升高。\n值得注意的是，这类安全性表现完全符合IBAT抑制剂类药物已知的作用机理预期。研究人员强调，胃肠道反应与肝酶指标变化均属可控范围，为后续临床开发提供了重要安全性依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186217776","title":"Mirum Pharmaceuticals预计2027年第一季度公布Volixibat治疗PBC的Vantage二期B阶段研究顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1186217776","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186217776?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:05","pubTimestamp":1777896314,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布，针对原发性胆汁性胆管炎（PBC）的Volixibat药物Vantage二期B阶段临床研究，预计将于2027年第一季度获得顶线数据结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156368450","title":"Mirum制药公司计划2026年夏季与FDA召开Volixibat治疗PSC的新药申请前会议 拟于2026年下半年提交NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1156368450","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156368450?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:03","pubTimestamp":1777896229,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布，针对Volixibat用于原发性硬化性胆管炎治疗的研发取得重要进展。公司已安排于2026年夏季与美国食品药品监督管理局举行新药申请前会议，此举标志着该药物研发进入关键阶段。根据公司规划，在完成Pre-NDA会议并获取监管机构反馈后，Mirum拟于2026年下半年正式提交Volixibat治疗PSC的新药申请。此次披露的监管时间节点，不仅体现了公司对研发进程的精准把控，也预示着该药物向商业化迈出了实质性步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101296019","title":"Mirum制药Volixibt实现瘙痒评分降低2.72分 较安慰剂组优势达1.64分（P<0.0001）","url":"https://stock-news.laohu8.com/highlight/detail?id=1101296019","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101296019?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:03","pubTimestamp":1777896199,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.旗下药物Volixibat在最新临床试验中展现出显著疗效。数据显示，该药物可使患者瘙痒评分平均降低2.72分，相较于安慰剂组取得的1.08分改善，治疗效果优势达到1.64分。这一差异具有高度统计学意义（P<0.0001），表明Volixibat在缓解瘙痒症状方面具有显著临床价值。\n研究结果进一步验证了Volixibat作为新型治疗方案的潜力。药物通过特异性作用机制靶向疾病根源，为相关患者群体提供了新的治疗选择。此次数据公布为Mirum Pharmaceuticals, Inc.后续的监管申报和商业化进程奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197260913","title":"Mirum Pharmaceuticals宣布Volixibat治疗原发性硬化性胆管炎的Vistas研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1197260913","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197260913?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896160,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布，其药物Volixibat在针对原发性硬化性胆管炎（PSC）患者开展的Vistas研究中，成功达到了预设的主要疗效终点。该重要里程碑标志着公司在肝胆疾病治疗领域的研发取得关键进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189451881","title":"Mirum制药宣布Brelovitug治疗慢性丁型肝炎的Azure-1研究2B阶段达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1189451881","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189451881?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:14","pubTimestamp":1777292063,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. (MIRM) 今日宣布，其针对慢性丁型肝炎病毒（HDV）的创新药物Brelovitug在Azure-1临床研究的2B阶段取得了重大进展，成功达到了预设的主要疗效终点。\n这一关键性成果标志着Brelovitug在治疗这一难治性肝脏疾病的发展道路上迈出了坚实的一步。丁型肝炎是一种严重的病毒性肝炎，目前全球范围内的治疗选择极为有限。Azure-1研究2B阶段的成功，为饱受该疾病困扰的患者带来了新的希望。\n公司表示，将基于此次获得的积极数据，与监管机构进行沟通，并积极推进该药物的后续临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121811592","title":"Mirum制药完成Livmarli®治疗罕见胆汁淤积性肝病三期扩展研究患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1121811592","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121811592?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:40","pubTimestamp":1773664821,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布已完成Livmarli®（maralixibat）针对其他罕见胆汁淤积性肝病的三期扩展研究（EXPAND）患者招募工作。\n该研究的顶线数据预计将于2026年第四季度公布。这项进展标志着Mirum在拓展罕见肝病治疗领域迈出关键一步，为患者带来新的希望。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124176149","title":"Mirum制药公司：Azure-1与Azure-4预计将于2027年在美国提交BLA申请并上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1124176149","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124176149?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:04","pubTimestamp":1772715899,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 旗下药物Azure-1和Azure-4有望在2027年向美国监管机构提交生物制剂许可申请（BLA），并计划同期实现商业化上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176149465","title":"Mirum Pharmaceuticals公布Brelovitug治疗慢性丁型肝炎病毒Azure临床项目最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1176149465","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176149465?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:02","pubTimestamp":1772715730,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.近日针对其候选药物Brelovitug在慢性丁型肝炎病毒感染治疗中的Azure临床研究项目，发布了最新动态更新。此次更新涵盖了该临床试验项目的关键进展与后续规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177135125","title":"异动解读 | Evercore上调目标价并看好药物潜力，Mirum Pharmaceuticals盘中大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177135125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177135125?lang=zh_cn&edition=full","pubTime":"2026-03-05 03:09","pubTimestamp":1772651362,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.  今日盘中股价大幅上涨5.07%，引起了市场的广泛关注。消息面上，知名投行Evercore ISI将Mirum Pharmaceuticals的目标价从101美元大幅上调至126美元，并重申了“跑赢大盘”的评级。具体来看，Mirum预计将在2026年第二季度获得实验性肝病药物volixibat的中期数据以及D型肝炎候选药物brelovitug的中晚期数据。券商预计，用于治疗原发性硬化性胆管炎的volixibat在全球的未调整峰值销售额可达12亿美元，这进一步增强了市场对公司未来增长潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101130484","title":"Mirum制药公司提交SEC文件：股东拟发售最高896万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101130484","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101130484?lang=zh_cn&edition=full","pubTime":"2026-02-26 06:20","pubTimestamp":1772058025,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Mirum Pharmaceuticals, Inc.已正式登记由售股股东发起的普通股公开发行计划。此次发售规模最高可达896万股，所有股份均由现有股东提供，公司本身不会从此次发售中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610100930","title":"Mirum Pharmaceuticals, Inc.跌0.54% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2610100930","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610100930?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:32","pubTimestamp":1770733977,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时32分，Mirum Pharmaceuticals, Inc.股票出现波动，股价快速跳水0.54%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为991.87%、627.18%、448.48%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.，振幅分别为52.69%、15.79%、12.95%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司， 专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223258a4940720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223258a4940720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115897314","title":"Mirum Pharmaceuticals宣布加拿大卫生部批准Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒","url":"https://stock-news.laohu8.com/highlight/detail?id=1115897314","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115897314?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:00","pubTimestamp":1770296417,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 近日宣布，加拿大卫生部已正式批准其药物Livmarli®用于治疗进行性家族性肝内胆汁淤积症（PFIC）患者的胆汁淤积性瘙痒。这一授权标志着该药物在加拿大市场的准入，为患有此种罕见肝病的患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156667431","title":"Mirum制药完成收购Bluejay Therapeutics 强化罕见病领域全球领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1156667431","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156667431?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:01","pubTimestamp":1769432497,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.近日宣布已完成对Bluejay Therapeutics公司的全面收购。这一战略举措显著拓展了Mirum在罕见病治疗领域的全球布局，进一步巩固了其行业领先地位。通过本次收购，Mirum获得了Bluejay Therapeutics在罕见肝病领域的创新研发管线及专业技术。这将为Mirum现有产品组合注入新的活力，增强其解决复杂罕见疾病的能力。此次交易不仅拓展了Mirum的全球业务版图，更彰显了其长期致力于罕见病治疗领域的坚定承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516480605","title":"Mirum Pharmaceuticals, Inc.2024财年实现净利润-87.94百万美元，同比增加46.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516480605","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516480605?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931269,"startTime":"0","endTime":"0","summary":"3月3日，Mirum Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-87.94百万美元，同比增加46.05%；其中营业收入为3.37亿美元，同比增加81.18%，每股基本收益为-1.85美元。从资产负债表来看，Mirum Pharmaceuticals, Inc.总负债4.45亿美元，其中短期债务1.71百万美元，资产负债比为1.51，流动比率为3.10。机构评级：截至2025年3月3日，当前有9家机构对Mirum Pharmaceuticals, Inc.目标价做出预测，其中目标均价为66.11美元，其中最低目标价为55.00美元，最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000148abe4acd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000148abe4acd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514651385","title":"Mirum Pharmaceuticals, Inc.盘中异动 早盘大幅跳水7.68%报46.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514651385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514651385?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666722,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Mirum Pharmaceuticals, Inc.股票出现波动，股价急速下跌7.68%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司，专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272232029632b0e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272232029632b0e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirumpharma.com","stockEarnings":[{"period":"1week","weight":-0.0539},{"period":"1month","weight":0.0623},{"period":"3month","weight":0.245},{"period":"6month","weight":0.2141},{"period":"1year","weight":1.1935},{"period":"ytd","weight":0.4493}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0041},{"period":"3month","weight":0.055},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.096}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mirum Pharmaceuticals, Inc.于2018年5月2日在特拉华州注册成立。该公司是一家生物制药公司，专注于识别、收购、开发和商业化用于使人衰弱的罕见和孤儿疾病的新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.06611},{"month":2,"riseRate":0.714286,"avgChangeRate":0.037723},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.043043},{"month":4,"riseRate":0.571429,"avgChangeRate":0.058316},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.02467},{"month":6,"riseRate":0.714286,"avgChangeRate":0.105618},{"month":7,"riseRate":0.571429,"avgChangeRate":0.062196},{"month":8,"riseRate":0.714286,"avgChangeRate":0.107618},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.04362},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.10761},{"month":11,"riseRate":0.714286,"avgChangeRate":0.084664},{"month":12,"riseRate":0.571429,"avgChangeRate":0.315468}],"exchange":"NASDAQ","name":"Mirum Pharmaceuticals, Inc.","nameEN":"Mirum Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mirum Pharmaceuticals, Inc.,MIRM,Mirum Pharmaceuticals, Inc.股票,Mirum Pharmaceuticals, Inc.股票老虎,Mirum Pharmaceuticals, Inc.股票老虎国际,Mirum Pharmaceuticals, Inc.行情,Mirum Pharmaceuticals, Inc.股票行情,Mirum Pharmaceuticals, Inc.股价,Mirum Pharmaceuticals, Inc.股市,Mirum Pharmaceuticals, Inc.股票价格,Mirum Pharmaceuticals, Inc.股票交易,Mirum Pharmaceuticals, Inc.股票购买,Mirum Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}